Drug cuts relapse rate of C. diff infection
Friday 04 February 2011
A new antibiotic has been shown to cut the rate of relapse by almost half of infections of the C. difficile bacterium, a growing scourge in hospitals worldwide, a study published Wednesday indicates.
The researchers examined a drug called Fidaxomicin, made by Optimer Pharmaceuticals of San Diego, and compared it to the antibiotic vancomycin, the only treatment against the infection approved in the United States and Canada.
By following 629 subjects over two years in a randomized study in which patients received one of the two treatments, those who took Fidaxomicin saw a 45 percent reduction in recurrences.
"Anybody who knows C. difficile recognizes that recurrences are the major problem with this disease," said Mark Miller of the Jewish General Hospital in Montreal, a co-author of the study in the New England Journal of Medicine.
"Anything that can reduce the recurrence rate, especially as dramatically as Fidaxomicin, is a very important milestone in the treatment of C. difficile."
C. difficile, which can cause anything from mild diarrhea to deadly colon inflammation, tends to afflict people in hospitals or long-term care facilities and can take hold after a patient has been on antibiotics.
Cases have been mounting in the past decade and 20 to 30 percent of patients who suffer from it once will get it again. Recurrent C diff is particularly hard to treat.
"There wasn't much interest in C. difficile for many years, because it wasn't considered a serious disease," said Miller.
"However, over the past decade the bacterium has mutated into something much more serious that has caused epidemics worldwide. It is particularly notorious for recurrences."
Fidaxomicin works by targeting bacteria inside the intestine and is minimally absorbed in the blood stream, so it kills the C. diff "without affecting the beneficial flora in the human gut which help stave off recurrences," the study said.
Life & Style blogs
Looking past the search results: Google 2.0 will 'build airports and cities' says report
Jennifer Lawrence nude pictures leaked: Reddit removes 'The Fappening' board dedicated to sharing naked pictures of celebrities
Anti-depressants can change how the brain works in just hours
iPhone 'Wave': iOS 8 hoax claims you can charge your iPhone in the microwave - you can't
The 'Angelina Jolie effect': Her mastectomy revelation doubled NHS breast cancer testing referrals
- 2 Friends 20th anniversary: Alison Jackson photographs reunited cast
- 3 A bottle of wine a day is not bad for you and abstaining is worse than drinking, scientist claims
- 5 Free U2 album: How the most generous giveaway in music history turned into a PR disaster
£75 - £90 per day + negotiable: Randstad Education Group: Are you a cover supe...
£30000 - £35000 per annum: Ashdown Group: Marketing Manager (CIM, B2B, MS Offi...
£22000 - £25000 per annum: Ashdown Group: A highly successful organisation wit...
£1 per day: Randstad Education Leeds: Job Purpose To work closely with the he...